Ginsenoside reprogramming microglia through the FGF/FGFR1 inhibits post traumatic stress disorder

Area of Science:

• Neuroscience
• Pharmacology
• Immunology

Background:

• Post-traumatic stress disorder (PTSD) is a debilitating mental health condition with currently unsatisfactory treatment outcomes.
• Existing treatments for PTSD, primarily pharmacotherapy and psychotherapy, often yield limited therapeutic effects.
• There is a critical need for novel therapeutic strategies to effectively manage PTSD.

Purpose of the Study:

• To investigate the therapeutic potential of ginsenoside, specifically Rg3, in a mouse model of PTSD.
• To elucidate the underlying molecular mechanisms by which Rg3 exerts its effects on PTSD.
• To identify fibroblast growth factor receptor 1 (FGFR1) as a potential therapeutic target for PTSD.

Main Methods:

• Administration of ginsenoside Rg3 to a mouse model of PTSD.
• Assessment of PTSD symptom severity in mice.
• In vitro studies using BV2 microglial cells to examine the role of Rg3 and FGFR1 in microglial activation.
• Analysis of microglial phenotype (M1 vs. M2) and neuronal apoptosis.
• Genetic manipulation of FGFR1 expression (knockdown and overexpression) in BV2 cells and in vivo models.

Main Results:

• Ginsenoside Rg3 significantly alleviated PTSD symptoms in the mouse model.
• Rg3 promoted an anti-inflammatory M2 microglial phenotype while suppressing the pro-inflammatory M1 phenotype.
• Rg3 up-regulated FGFR1 expression in microglia, which suppressed excessive microglial activation and reduced neuronal apoptosis.
• Knockdown of FGFR1 abolished the therapeutic effects of Rg3 in vivo, confirming FGFR1 as an essential target.
• Overexpression of FGFR1 in BV2 cells reversed pro-inflammatory effects.

Conclusions:

• Ginsenoside Rg3 demonstrates significant therapeutic potential for PTSD.
• The mechanism involves Rg3-mediated upregulation of FGFR1, leading to modulation of microglial polarization and neuroprotection.
• FGFR1 is identified as a crucial molecular target for PTSD treatment.
• Rg3 represents a promising candidate for the development of novel PTSD therapeutics.